Previous 10 | Next 10 |
2023-07-28 17:01:08 ET Summary Vertex is a $90bn market cap Pharma giant with a monopolistic control of the cystic fibrosis industry. CRISPR Therapeutics is an obscure - to some - Swiss Pharma focused on gene therapy, leveraging Nobel Prize winning technology. The two companie...
2023-07-26 19:53:59 ET Summary FDA review date of CRISPR Therapeutics AG exa-cel for the treatment of patients with severe sickle-cell disease has been set for December 8, 2023. FDA review date of exa-cel for the treatment of patients with transfusion-dependent beta thalassemia ha...
2023-07-25 08:26:45 ET Summary CRISPR Therapeutics is a leading biotech company, currently developing gene-editing techniques to cure hereditary diseases, with promising projects underway. The company's Q1 2023 revenue was 100 M USD, derived from R&D collaboration agreements w...
2023-07-25 05:06:26 ET Summary CRISPR Therapeutics, leading in gene-editing technology, progresses with exa-cel for treating beta-thalassemia, severe sickle cell disease, and type 1 diabetes. Despite considerable volatility and risk, CRSP shows a robust cash position and revenue g...
2023-07-22 09:45:00 ET What does "off-the-shelf" mean to you in the context of advanced cancer treatments? If you said something along the lines of "a therapy that doesn't need lots of customization for each patient before being used," you're on the right track. For biotechs like Cari...
2023-07-21 08:15:00 ET Investors looking for stocks with explosive growth potential would do well to take a gander at the biotech industry. Clinical and regulatory wins can fuel excellent stock market performances for companies in the sector in a relatively short period, say a year. But sho...
2023-07-21 05:30:00 ET CRISPR Therapeutics (NASDAQ: CRSP) may be a few months away from a transformation. The company itself isn't changing, but its financial picture may be about to do so. That's because by year-end, regulators will make a decision about what could become CRISPR's ...
2023-07-19 09:03:12 ET bluebird bio ( NASDAQ: BLUE ) added ~8% pre-market Wednesday after Bank of America upgraded the stock to Buy from Neutral, citing a potential FDA approval for its new gene therapy, lovo-cel, targeted at patients with sickle cell disease (SCD). The firm...
2023-07-19 01:15:36 ET Summary ARK Invest's 13F portfolio value increased by approximately 4% from $14.55B to $15.10B in Q2 2023, with holdings increasing from 221 to 222. The firm established a new 0.69% stake in Palantir Technologies while increasing stakes in Coinbase Global, U...
2023-07-17 15:02:01 ET Summary CRISPR Therapeutics, a biotech company specializing in gene-based medicines, has submitted applications to the FDA for its lead product, Exa-cel, a gene-edited cell therapy for severe sickle cell disease and transfusion-dependent beta thalassemia. De...
News, Short Squeeze, Breakout and More Instantly...
CRISPR Therapeutics AG Company Name:
CRSP Stock Symbol:
NASDAQ Market:
CRISPR Therapeutics AG Website: